Downloading...
Download

Otcqb

What Is the Over-the-Counter (OTC) Market and How Does It Work? What Is the Over-the-Counter (OTC) Market and How Does It Work? The over-the-counter (OTC) market is a crucial yet often misunderstood part of the financial system. Unlike centralised exchanges, OTC markets offer a decentralised way to trade various securities, from bonds to currencies. This article explores how the OTC market works, its instruments, and the opportunities and risks it presents for traders and investors alike. What Is the OTC Market? The over-the-counter market meaning refers to the OTC marketplace, a decentralised network where financial assets are traded directly between buyers and sellers, rather than through a centralised exchange like the NYSE. This OTC definition highlights that trades happen via private negotiations, often facilitated by brokers or dealers. OTC markets cover a wide range of assets, including bonds, derivatives, and unlisted stocks. This market is popular for assets that are either too niche or illiquid to be traded on traditional exchanges. For example, many corporate bonds and complex derivative products are commonly traded OTC. One of the key features of the OTC market is its flexibility. Since it’s not bound by exchange rules, traders can customise contracts, including factors like trade size and terms. However, this also means less transparency, as there’s no central exchange to standardise prices. Investors also face greater counterparty risk—the risk that the other party in a trade may default. Prices can vary, and buyers often face wider bid-ask spreads due to lower liquidity. Despite this, OTC market trading plays a crucial role in global finance, especially for institutions looking for bespoke solutions or access to less commonly traded assets. Although not as accessible to retail traders, it’s vital for institutional investors, corporations, and hedge funds. How Does the Over-the-Counter Market Differ from Exchanges? The over-the-counter market and traditional exchanges both facilitate the trading of securities, but they operate in fundamentally different ways. Check out how they differ: 1. Centralisation - OTC: Decentralised, with trades occurring directly between two parties, typically via brokers or dealers, often through phone or electronic means. - Exchanges: Centralised, with all trades happening in a formal, regulated environment (e.g., the NYSE), ensuring consistent pricing. 2. Regulation - OTC: OTC trading is regulated but with fewer reporting requirements and more flexible trading terms. - Exchanges: Highly regulated, with strict oversight from government bodies (e.g., SEC) to provide transparency and protect investors. 3. Pricing Transparency - OTC: Prices are negotiated and can vary between trades. This lack of a central order book means there’s often less price visibility. - Exchanges: Transparent pricing with public order books and visible trade histories, ensuring all market participants see the same prices. 4. Liquidity - OTC: Liquidity can be lower, and bid-ask spreads can be wider, particularly for less frequently traded instruments. - Exchanges: Typically higher liquidity with narrower spreads due to the larger pool of buyers and sellers. 5. Contract Standardisation - OTC: Contracts can be customised to suit the needs of the parties involved, which is common with derivatives. - Exchanges: Contracts are standardised in terms of size, quality, and other conditions, offering uniformity across trades. 6. Counterparty Risk - OTC: Higher counterparty risk since there's no intermediary guaranteeing trades. - Exchanges: The exchange itself acts as an intermediary, reducing the risk of default. Different OTC Markets The OTC market is decentralised, but it has several key venues or platforms where securities are traded. Each market offers a different level of access and regulation. Key over-the-counter market examples include: OTCQX This is the top-tier OTC market, where companies must meet higher financial and reporting standards. It’s known for featuring well-established companies, including international firms and large corporations that don’t wish to list on major exchanges but still want access to US investors​. OTCQB Often called the "Venture Market," this tier caters to smaller or growing companies. It has less stringent requirements than OTCQX but still requires regular financial reporting and compliance with some SEC guidelines​. Pink Open Market Also known as the "Pink Sheets," this is the most speculative and riskiest OTC market. Companies listed here have minimal financial requirements, making it home to smaller, more volatile firms. Investors should approach this arena with caution due to the higher risk of lack of transparency​. Forex, Bonds, and Commodities Since OTC markets are decentralised, they are not as heavily regulated as exchange-traded markets. However, they are still subject to regulatory oversight in key jurisdictions to ensure transparency, protect participants, and prevent fraud. Types of Instruments Traded on the OTC Market The OTC market is home to a wide variety of financial instruments, many of which don’t fit neatly within the rigid structures of formal exchanges. These instruments are often more customised or involve companies that aren’t listed on major exchanges. Derivatives The OTC market is one of the primary venues for trading derivatives—an instrument based on the price movements of an underlying asset. OTC derivatives examples include CFDs, swaps, forwards, and options. These contracts are often tailored to meet the specific risk management needs of the parties involved. For instance, interest rate swaps help companies hedge against changes in borrowing costs​. The key difference between exchange-traded and OTC derivatives lies in standardisation: exchange-traded derivatives are standardised, while OTC derivatives are customised to suit specific requirements. Unlisted Stocks Shares of smaller companies that don’t meet the listing standards of major exchanges are traded OTC. These stocks can range from well-established foreign companies (through mechanisms like American Depositary Receipts) to speculative, early-stage firms​. Bonds Government and corporate bonds are frequently traded over the counter. Since bonds are typically issued in large quantities and often have specific terms, the OTC market allows for more flexibility and customisation compared to exchanges. This also includes municipal bonds, which are important for financing public projects​. Commodities Some commodities, such as gold or oil, can also be traded OTC, offering buyers and sellers a flexible way to arrange deals that aren’t subject to standardised exchange rules​. Currencies The foreign exchange (forex) market, the largest OTC market globally, involves the trading of currency pairs. While it’s a specialised space, it’s essential for international trade and finance​. Want to explore a world of currency pairs and stock and commodity CFDs? Head over to the TickTrader trading platform by FXOpen to get started. Advantages and Disadvantages of OTC Markets The OTC market offers both significant advantages and notable disadvantages, making it an important but complex space for investors. Advantages - Flexibility: OTC markets allow for greater flexibility in terms of trade size, timing, and contract structure. This is particularly valuable for derivatives and bonds, where customised terms are often crucial for hedging or managing financial risks​. - Access to Niche Markets: Many securities traded OTC, like unlisted stocks or foreign bonds, aren’t available on major exchanges. This provides investors with access to a broader range of opportunities, particularly in niche or emerging markets​. - Less Stringent Requirements: For companies, the OTC market offers a way to raise capital without the heavy regulatory burden of a stock exchange listing. This makes it a viable option for smaller or newer companies looking to grow​. Disadvantages - Lower Transparency: One of the biggest downsides of OTC trading is its lack of transparency. Prices are often not publicly available, making it harder for investors to gauge fair value​. - Higher Counterparty Risk: Since there is no centralised clearinghouse, the risk that one party might default on a trade is higher in OTC venues. This can be particularly risky in volatile conditions​. - Liquidity Issues: Liquidity can be much lower in OTC markets, especially for niche or less frequently traded securities. This means that finding a buyer or seller at the desired price may be more challenging, resulting in wider bid-ask spreads​. The Bottom Line The OTC market offers unique opportunities for traders seeking flexibility and access to specialised securities. However, it comes with its own risks. Understanding these factors is key to navigating this dynamic marketplace. To potentially mitigate risks, traders choose regulated, well-established brokers with a long history. To explore trading opportunities in the forex, stock, and commodity markets, consider opening an FXOpen account and gain access to four advanced trading platforms, blazing-fast execution speeds, and competitive trading costs. FAQ Is Forex an OTC Market? Yes, forex is an over-the-counter (OTC) market. It operates through a global, decentralised network where currencies are traded directly between participants, rather than through a central exchange. Retail traders access this market via brokers, allowing them to trade currency pairs 24/5. What Is OTC in the Stock Market? In the stock market, the OTC meaning refers to trading securities outside of formal exchanges. These are often smaller companies that don’t meet the requirements for major exchanges like the NYSE and are traded via a broker-dealer network. What Are Examples of OTC Financial Products? Examples of OTC financial products include bonds, derivatives like swaps and options, unlisted stocks, and currencies. These products are traded directly between parties, often through brokers, without a central exchange. What Is an Example of an OTC Platform? An example of an OTC platform is OTC Markets Group, which facilitates the trading of unlisted stocks through tiers like OTCQX, OTCQB, and Pink Open Market. What Is OTC in the Crypto Market*? In the cryptocurrency market*, OTC trading involves large transactions of digital assets conducted directly between buyers and sellers, often through brokers, bypassing traditional exchanges for greater privacy and flexibility. *At FXOpen UK, Cryptocurrency CFDs are only available for trading by those clients categorised as Professional clients under FCA Rules. They are not available for trading by Retail clients. This article represents the opinion of the Companies operating under the FXOpen brand only. It is not to be construed as an offer, solicitation, or recommendation with respect to products and services provided by the Companies operating under the FXOpen brand, nor is it to be considered financial advice.
Education
by FXOpen
1
$SFRX Long with price target of 2020 high 0.0179¢Seafarer Exploration’s SeaSearcher drone is set to take the treasure-hunting world by storm The current SeaSearcher prototype, getting put to the test in Florida As any frequent viewer of the Discovery Channel will know, the search for sunken treasure typically involves sifting through the sand, just hoping to unearth gold or silver. The SeaSearcher underwater drone, however, may soon point clients right to the booty. Currently in functioning prototype form, the battery-electric SeaSearcher is being developed by Florida startup Seafarer Exploration. It was designed by engineer Tim Reynolds, CEO of partnering company Wild Manta. The vehicle's big claim to fame is that it can detect – and differentiate between – various types of metal buried up to 10 meters (33 ft) beneath the seabed, creating and relaying a 3D digital map of their location. "I've been given the rights to salvage old Spanish and other types of wrecks along the coastline, here in Florida," Seafarer CEO Kyle Kennedy told us. "All these ships used to dock in Havana, they would load up with gold from the New World, and head up the Gulf Stream before heading across the ocean. Storms would sink them, on their routes. There's over a thousand of these shipwrecks, but the problem is, there's never been equipment that would show you where gold and silver was, under the sand." The exact means by which the SeaSearcher does allegedly show you is a closely guarded trade secret. However, we have been told that the drone can descend to depths of up to 100 m (328 ft), then cruise about 1 m (3 ft) above the seafloor, emitting electromagnetic, RF and acoustic waves of varying modulation formats as it does so. Utilizing machine-learning-based algorithms running in real time, it analyzes the manner in which any buried metal objects are "energized" by those waves. As a result, the vehicle is reportedly able to determine the depth at which those objects are located, along with the type of metal they're made of. The SeaSearcher's operator interface displays a 3D map showing the location of buried metal objects Seafarer Exploration In a field test recently conducted at a Florida wreck site, the SeaSeacher didn't find any gold or silver, but it is claimed to have identified brass, iron, copper, aluminum, lead and stainless steel items. The geographical location of the detected metals is determined in two ways. First of all, since radio waves don't travel well through the water, the SeaSearcher tows a floating buoy along the surface above itself. The GPS coordinates of that buoy are recorded and transmitted to the crew, aboard a nearby support boat from which the SeaSearcher was launched. That said, strong currents or rough weather can cause the buoy to end up a fair distance away from the drone – after all, the cable by which it's towed has to contain some slack, meaning it doesn't go straight down to the SeaSearcher. For that reason, a triangulation system developed by the US Navy can also be used. It incorporates a submerged platform which hangs over the side of the support boat, where it sends and receives sonar pings to and from the drone. A rendering of the 2nd-generation SeaSearcher, which will be optimized for use in a towfish configuration Seafarer Exploration The SeaSearcher can be used as an ROV (remotely operated vehicle), an AUV (autonomous underwater vehicle) that follows a preprogrammed search pattern, or in a towfish setup, wherein it's towed behind a boat. Since Seafarer doesn't want competitors getting their hands on the technology and figuring out precisely how it works, plans call for the company to instead offer the SeaSearcher and an operator as a service to treasure-hunting clients. Kennedy believes that the service should be available within six months. In the meantime, he hopes to raise funds by using the drone to discover some sunken treasure of his own. "The world doesn't believe that this device works, right now," he said. "As soon as we prove that it works on treasure, we'll do some white papers and independent tests and all that good stuff. But right now, all I need it to do is show me some massive amounts of gold and silver, and then I don't really care what the world thinks." Learn More Here: newatlas.com
OTC:SFRXLong
by astrothtrader
2
Augusta Gold (USA: $AUGG) Holding Strong On Insider Buying!⛏️Augusta Gold Corp., a junior exploration company, engages in the acquisition and exploration of mineral properties in the United States. It primarily explores for gold, silver, and other metals. The company holds interests in the Bullfrog gold project located in the Bullfrog Hills of Nye County, Nevada. It also owns, controls, or has acquired mineral rights on Federal patented and unpatented mining claims in the state of Nevada for the purpose of exploration and potential development of metals on a total of approximately 7,800 acres of land. The company was formerly known as Bullfrog Gold Corp. and changed its name to Augusta Gold Corp. in January 2021. Augusta Gold Corp. was incorporated in 2007 and is headquartered in Vancouver, Canada.
OTC:AUGGLong
by Bullishcharts
2
Augusta Gold (USA: $AUGG) Nearing The Golden Pocket! 🌟Augusta Gold Corp., a junior exploration company, engages in the acquisition and exploration of mineral properties in the United States. It primarily explores for gold, silver, and other metals. The company holds interests in the Bullfrog gold project located in the Bullfrog Hills of Nye County, Nevada. It also owns, controls, or has acquired mineral rights on Federal patented and unpatented mining claims in the state of Nevada for the purpose of exploration and potential development of metals on a total of approximately 7,800 acres of land. The company was formerly known as Bullfrog Gold Corp. and changed its name to Augusta Gold Corp. in January 2021. Augusta Gold Corp. was incorporated in 2007 and is headquartered in Vancouver, Canada.
OTC:AUGGLong
by DEXWireNews
1
PeakBirch Commerce (USA: $PKBFD) Low-Float NFT Play Could See 🌙PeakBirch Logic Inc. engages in the e-commerce sales and delivery of cannabis-related and cannabidiol (CBD) containing products. The company distributes vaporizers, CBD related accessories, and ancillary products for aromatherapy and other applications, as well as CBD tinctures, topicals, edibles, and other products. It sells its products through Namastevapes.com, Everyonedoesit.com, LiftedCBD.com, Leafscience.com, and Lifted.com portals. PeakBirch Logic Inc. is headquartered in Vancouver, Canada.
PLong
by RedHotStocks
2
Progressive Care (USA: $RXMD) Is A Top Choice Penny Stock 👌Progressive Care, Inc., through its subsidiary, Pharmco, LLC, provides prescription pharmaceuticals to individuals and institutions in south Florida. The company operates a retail pharmacy that specializes in the sale of anti-retroviral medications and related patient care management; the sale and rental of durable medical equipment (DME), such as hospital beds, oxygen supplies, power wheelchairs, scooters, walkers, and other related equipment and accessories; and the supply of various prescription medications to long term care facilities. It also provides long term care solutions to skilled nursing facilities, assisted living facilities, retirement centers and communities, doctors' offices, and clinics. In addition, the company purchases, repackages, and dispenses prescription and non-prescription pharmaceutical products for its long term care customers. Further, it offers computerized maintenance of patient prescription histories; third party billing; consultant pharmacist services consisting of evaluation of monthly patient drug therapy and monitoring the institution's drug distribution system, as well as home service and maintenance, defective product replacements, and free home installation and instruction services; and data analytics services to support health care organizations. Progressive Care, Inc. was founded in 2005 and is based in Hallandale Beach, Florida.
RLong
by DEXWireNews
HUMBL (USA: $HMBL) Gearing Up For A Big Move In 2022 ⚙️HUMBL, Inc., a digital commerce platform, connects consumers, freelancers and merchants in the digital economy worldwide. The company offers HUMBLPAY that connects consumers, freelancers, and merchants in the digital economy to share and pay; and HUMBLMARKETPLACE that enables merchants to list and sell goods by authenticating through HUMBL Token Engine and HUMBL Origin Assurance technologies to improve merchants ability to trade, track, and pay for assets, as well as HUMBL Pay web checkout integrations. It also provides HUMBLFINANCIAL, a platform that provides digital asset investment services. The company was formerly known as Tesoro Enterprises, Inc. and changed its name to HUMBL, Inc. in February 2021. HUMBL, Inc. is based in San Diego, California.
OTC:HMBLLong
by DEXWireNews
3
Clearday (USA: $CLRD) Appoints John Bergeron As CFO 👨‍💼Clearday, Inc. operates as a non-acute longevity health care services company. It operates residential memory care communities in four U.S. states. It offers Clearday at Home, a digital service that provides families with resources and content to provide care at home for loved ones with Alzheimer's, dementia, or other lifestyle limiting conditions; the Clearday Network, a B2B alliance program that empowers third party, non-acute home care agencies, home health services businesses, and other aligned partners to offer care services based on the Clearday at Home platform; and Clearday Clubs, membership-based daily care destinations that enrich the lives of those with dementia, Alzheimer's, or other lifestyle-limiting chronic health conditions. The company is based in San Antonio, Texas.
OTC:CLRDLong
by DEXWireNews
$NUKK - Invest in Institutions for Under One DollarI know, I know... Another OTC stock that "is going to moon" ! Actually, this is a legitamite company that has an incredible background and alot of potential. This thing will not stay under $1 for long. This is not some pump n dump stock. This is a true long term investment that could change lives not only for investors, but also people who use Nukkleus and their products. Now starting off, this may look bad as shares have dropped from 2.20's area to .40's, but its only due to Craig Marshak getting divorced by his wife and her selling all 482,000 shares that he had owned. So truly, this is a DIAMOND IN THE ROUGH especially with all the DD there is to offer. From their website:        Nukkleus combines its world-class technology with institutional digital asset and exchange execution services, giving Nukkleus the full-service offerings needed to compete effectively in the multi-asset world. Nukkleus is a digital financial services company with a suite of financial technologies to provide institutional counterparts with unique access to global liquidity and a comprehensive suite of products and services. Our technology delivers institutional-grade access to traditional and digital asset markets globally along with a UK FCA registered EMD agent for handling of professional and accredited client funds and conducting cryptocurrency conversion into fiat currencies.       For the people that just want the important stuff, what they are known for is Digital RFQ, being an institutional cyrptocurrency exchange. They are also working their way into the NFT auction space. Below is my list of DD that are from an interview with COO of Nukkleus, Jamie Kuhrshid. (Former VP at Credit Suisse, Executive Director at Goldman Sachs and Royal Bank of Scotland) They are currently the ONLY regulated Cryptocrrency exchange in europe for Institutions. (Currently 130+ Institutions) Once they prove how good they are, they plan to open for retail investors and rival coinbase. $NUKK currently runs the software for $FXDD. They are currently talking with Large UK Auction house about a partnership to deal with NFTs. SUPER LOW FLOAT at 19 Mil. $17 Million in Assets. $19 Million in Revenue in 2020. Penny Stock Exempt! Also Pink Current so you know they're not some shady company. They currently have 24 Press Release lined up and are waiting to use them at the right time. They would prefer to use them to their advantage. Right now, they are working with 5 Large NFT clients in the Luxury car industry. Sadly, he could not expand on who the exact brands were but during the interview there were a lot of F1 references so one can only assume. They currently have the application to uplist to OTCQB in hand. As Jamie puts it, "We were basically invited" and plan to also uplist to the NASDAQ shortly after. Have partnered with Polygon (Backed by Mark Cuban) and Grassroots to integrate the recycling of municipal waste using Blockchain. Aso have been working with RedCross . Jamie also mentions that they have been in talks with one of the largest brokerages in the world about a possible acquisition. (MAJOR MONEY) There is a ton more that I could go over from the interview but I'll just leave the link here: GoToMeeting Transcripts       Also, did I forget to mention anything about the CEO of Nukkleus, Emil Assentato? Let me fill you in. Former CEO and Current Chairman at Tradition North America, one of the leading inter-dealer brokers in the world, and a subsidiary of Compagnie Financiere Tradition, a leading global brand in inter-dealer broking listed on the Swiss Stock Exchange. Currently trading near $110. He has over 30 years of Wall Street leadership in Institutional Sales, Marketing and Senior Management. Mr. Assentato and his team were the founding shareholders of FXDD in 2002, and pioneered the brand in the early days of the retail forex industry. This is just the beginning for Nukkleus. More to come....
NLong
by Jsun_13
OZSC ZonesI keep checking my charts over and over to see if fi missed something about OZSC. What i learned since i bough in (around 0.006) is that OZSC has tendency to make red wicks going Upwards, strange a bit but every time they closed red for a multiple days it just created a new triangle to break from over and over. I believe now that with SMA 13 that crossed SMA 50 for the first time in History of OZSC , this becomes a crucial support for the bigger up trend to follow. OTCQB uplisting would be the catalyst for a bigger movement, followed by bigger news. My realistic target is $2, my Optimistic target is $5 Do your own DD and stick to your plan.
OTC:OZSCLong
by imNemo
1
Sureshot? SHMP falling wedge to 150% ? #OTCMarkets #OTCBB #OTCQBSHMP appears to be operating in a lovely falling wedge that will likely be coming to it's end at the end of August . Sounds like a perfect late Summer setup for a 100% or more rise ? Looking at it's previous rises it has a similar appearance . Right now it's at .045 and I'd expect it to continue down this falling wedge pattern to probably .025 give or take . My target if it then goes up would be at least that local .618 fib near .0645 which would be 150% approx . but I'm no math expert ! and you should dyor - do your own research . Also I like eating shrimp ( and this is a shrimp company ! ) I would also expect a TD Seq 9 in red to be hit on the 6hr chart ( though we could definitely hit those on the 4hr or 1 day or other timeframe also . ) And the rsi 6hr should be below 30 before this is looking like a buy imo . Keep in mind there is a Gann Fan here that could also see this go to 10 , 12 , or 15 cents but that would be a lot ! Let's keep an eye on this. I've got Trading View alert set for 4hr rsi crossing down 30 just so I don't miss it . Thank you .
OTC:SHMP
by shimmeringpath
Add $SNWV to the top of your watchlist. Trading at $0.20 w/...===================== SNWV (SANUWAVE Health, Inc.) Float: 44.01M Alert Price: $0.205 Valuation: $0.55 (Zacks Small-Cap Research) Chart Analysis Investor Presentation Website | Recent News ======================== Members, We promised to a bring you an up-and-coming biotech company that has the potential to double its share price in the immediate future. So without further ado, we ask that you turn your immediate attention to SNWV (SANUWAVE Health Inc.). Health care is big business, and researchers are always working on the next big treatment option that will revolutionize the industry. One area that doesn’t get much attention despite having a big need is the treatment of diabetic foot ulcers (DFUs), where SNWV has been focusing its efforts. Diabetes is a horrible disease, and especially as we continue to see the demographics of many countries get older, this is going to be a larger and growing market in the years to come. With a market cap of less than $30 million, SNWV is still relatively small and unknown, but we have a feeling that is going to change very soon… We see significant growth opportunities available for the SNWV thanks to the cutting edge technological advancements they have made thus far. Why their Technology is so Special SNWV has developed a technology that utilizes high-energy acoustic shock waves to help restore the natural healing process. Pulsed Acoustic Cellular Expression (PACE) is both proprietary and patented by Sanuwave, and is the prized technology that helps repair tissues and allows them to regenerate. Currently, patients with DFU simply have their wounds cleaned and are bandaged back up. With this technology, the wound can heal and improve both the quality of life for a patient and increase their lifespan. DFUs can end up leading to amputation and 65% of patients die within five years. SNWV currently has two products in their pipeline that could be lifesavers for patients in this multi-billion dollar market! dermaPACE, the company’s flagship device, is already FDA-approved in the US for treating DFUs, and has passed European standards for a CE marked device as well. The device has experienced growing demand into other parts of the world, and could see an even larger growth in demand as it becomes available to more patients. orthoPace, while not yet FDA-approved, is also a CE Marked device passing European standards. Both of these products utilize the PACE technology. SNWV has an All-Star CEO Kevin Richardson is the CEO of Sanuwave, and he’s got a good track record when it comes to health care. He previously developed “The Vac,” which is used for Negative Pressure Wound Therapy. The company that owned the product, Kinetic Concepts, went on to generate over $1 billion in revenue, and was ultimately taken private for around $11.5 billion. Sanuwave is nowhere near that value today, but with the guidance of its CEO, there’s a lot of hope that it could achieve similar success. Richardson has demonstrated an eye for value and opportunity, and his leadership ability will certainly help grow Sanuwave’s brand. SNWV Reports Record 2018 Financial Results SNWV witnessed revenue growth of +151% in 2018! The increase in revenue for 2018 was primarily due to initial sales of dermaPACE devices in the United States, an increase in sales of orthoPACE devices in Asia/Pacific and the European Community, as compared to the prior year, as well as higher sales of new applicators. 2018 was filled with achievements meant to prepare SANUWAVE for rapid revenue growth beginning in 2019 and beyond. The stage is set and it is now dependent on our ability to execute the well developed plan of placing 100 dermaPACE devices in the US in 2019. Our vision is to be viewed by the world as a diverse, compassionate global family that provides positive impact on life and environment, one shock at a time. The goal for SANUWAVE remains unchanged and that is to have a dermaPACE device anywhere and everywhere a DFU is treated. SNWV's Bullish Outlook for 2019 Sanuwave saw strong growth in 2018 and it expects 2019 to be even better, with device sales expected to reach 120 units. In five years, Sanuwave hopes to have as many as 2,000 placements and expects revenues to reach over $100 million. Additionally, the company is looking to continuing to build on its international presence this year as it hopes to expand into three to four more countries. There you have it, SNWV appears to be a clear cut winner from head to toe. The Company has: Strong Revenue Growth Innovative Products FDA Approval Seasoned Management Team A valuation that is +175% above its current share price Bullish Outlook for 2019 It's no surprise why we think SNWV's share price could double in the very near future. That being said, we suggest that you start your research now, and add SNWV to the top of your watchlist. About SANUWAVE Health, Inc. SANUWAVE Health, Inc. (www.sanuwave.com) is a shock wave technology company initially focused on the development and commercialization of patented noninvasive, biological response activating devices for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures. SANUWAVE’s portfolio of regenerative medicine products and product candidates activate biologic signaling and angiogenic responses, producing new vascularization and microcirculatory improvement, which helps restore the body’s normal healing processes and regeneration. SANUWAVE applies its patented PACE technology in wound healing, orthopedic/spine, plastic/cosmetic and cardiac conditions. Its lead product candidate for the global wound care market, dermaPACE®, is CE Marked throughout Europe and has device license approval for the treatment of the skin and subcutaneous soft tissue in Canada, Australia, and New Zealand. In the U.S., dermaPACE®, is currently under the FDA’s Premarket Approval (PMA) review process for the treatment of diabetic foot ulcers. SANUWAVE researches, designs, manufactures, markets and services its products worldwide, and believes it has demonstrated that its technology is safe and effective in stimulating healing in chronic conditions of the foot (plantar fasciitis) and the elbow (lateral epicondylitis) through its U.S. Class III PMA approved OssaTron® device, as well as stimulating bone and chronic tendonitis regeneration in the musculoskeletal environment through the utilization of its OssaTron®, Evotron® and orthoPACE® devices in Europe, Asia, and Asia/Pacific. In addition, there are license/partnership opportunities for SANUWAVE’s shock wave technology for non-medical uses, including energy, water, food, and industrial markets. Company Highlights & Recent Developments Accomplishments in 2018 Hired Shri Parikh, President Healthcare Received reimbursement tracking for DFU procedure Signed Premier Shockwave as the exclusive distributor for the VA and IHS Added Science Advisor, Dr. Perry Mayer JWC published a peer review article on SANUWAVE’s 336 double blind study Added 15 countries to international distribution Signed with NFS to help finance equipment growth Goals for 2019 100 US Placements ; 300 certified users Reimbursement; finish with at least 10 million covered lives Launch 2-3 domestic clinical studies Add 3-4 new countries Add Additional science advisors Add other key senior management hires To help facilitate its growth, Sanuwave partnered with Premier Shockwave, Inc., a leader for shockwave treatments used for podiatric and orthopedic applications. By working with Premier Shockwave, Inc., Sanuwave has been able to gain access into key markets in the United States, such as: Veteran’s Administration (VA) Indian Health Services (IHS) Tribally Operated Healthcare Services US Military Treatment Facilities (MTFs) Currently, Premier Shockwave serves and has access to more than 30 VA hospitals and MTFs. We expect another record breaking year for SNWV During the past year, the company hit record sales numbers and expanded into 15 new countries via partnerships, which could make this year even better. However, Sanuwave is not stopping there. It’s continuing on plans for international expansion, and it expects shipments to hit a new record in 2019. Find out which countries and regions are key to Sanuwave’s international growth by signing up for our exclusive report. Sanuwave is also continuing to conduct clinical studies, with between two and three planned for the U.S. to help with the rollout of its products. It’s also working with insurance providers to get reimbursement coverage, which would undoubtedly lead to more adoption of its products, and help grow sales even more. Sanuwave is an exciting young company that’s still in its early-growth stages. With great products that solve a big problem in a big market, it has all the ingredients for significant and rapid growth. Recent Developments SANUWAVE Receives U.S. and European Patents for Intracorporeal Shockwave Systems for Treating Blood Vessels in Cardiology and Endovascular Fields SUWANEE, GA, April 02, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- SANUWAVE Health, Inc. (SNWV), an emerging medical technology company focused on the development and commercialization of noninvasive, biological response activating devices in regenerative medicine, received United States Patent US 10,238,405 on March 26, 2019 entitled “Blood Vessel Treatment with Intracorporeal Pressure Shock Waves” which has a patent life up to January 2032 from the U.S. Patent and Trademark Office (USPTO). This U.S. patent includes eight (8) claims related to the special construction of the intracorporeal shockwave apparatuses/systems comprising of a catheter size fit within a blood vessel, with one or multiple shockwave applicators that include shockwave generation sources disposed within an ellipsoidal reflector oriented perpendicular to the catheter longitudinal central axis of symmetry, which can produce focused shockwaves oriented towards vessel’s wall where the plaques are forming. The shockwave generation sources can be electrohydraulic, laser-based, electromagnetic, or piezoelectric. Also, SANUWAVE received European Patent EP 3,117,784 on December 26, 2018 entitled “Usage of Intracorporeal Pressure Shock Waves in Medicine”, which has an expiration date in July 2030 from the European Patent Office (EPO). This patent is validated in designated countries including Denmark, Finland, France, Germany, Great Britain, Holland, Ireland, Italy, Norway, Spain, and Sweden. The European patent includes fifteen (15) claims related to the special construction of the intracorporeal shockwave devices/systems comprising of a catheter size fit within at least one of a blood vessel, graft, or artificial blood vessel, with at least one balloon, and at least one or multiple shockwave generation sources coupled to the catheter. The intracorporeal shockwave device/system can be used to treat plaques and obstructions together with distal protection devices, to protect the flowing of dislodged plaque particles to the heart or brain. The shockwave generation sources can be electrohydraulic, laser-based, electromagnetic, or piezoelectric. The use of intracorporeal shockwave systems can constitute a new therapy option in treating cardiovascular or endovascular arterial systems for partial obstructions due to atherosclerotic plaques or vulnerable plaques. The intracorporeal shockwave systems described in these patents can be used to treat blood vessels’ plaques and partial obstructions in conjunction with distal protection devices, to protect the flowing of dislodged plaque particles to the heart or brain, which can possess significant health hazard for the patient. Such intracorporeal shockwave systems can be also used to promote accelerated healing after angioplasty or stenting using metal bare stents or drug eluting stents; or to treat in-stent restenosis. “We have an extensive and growing Intellectual Property (IP) portfolio. It will make sense to maintain and grow some of the IP portfolio on our own as we develop our wound business. For other non-medical and various medical markets, we prefer to find good corporate partners, possibly in the atherosclerotic, cardiology, or endovascular space to bring the IP to a commercial stage. We plan to pursue monetization and partnering of our IP portfolio on a selective basis and will engage with vetted partners before the end of the year,” commented Kevin A. Richardson, II, CEO and Chairman of the Board at SANUWAVE. SANUWAVE Health Inc., and its wholly owned subsidiary SANUWAVE, Inc., now have 52 medical patents (issued or pending) and 22 non-medical patents (issued or pending) related to shockwave technology. Market Outlook The Market Could Potentially Hit Close to $50Billion by 2024 In the United States, as many as 1.9 million new cases of DFU are diagnosed every year. And in five years, it’s estimated that the market for DFU and pressure ulcers will potentially reach $4.9 billion. It’s a big industry that is in direct need of improved treatment options, and Sanuwave could help fill that void. Market Opportunity with The dermaPACE® System U.S Market Diabetic Foot Ulcers - $4B+ market size. 29 million people living with diabetes and 86 million pre-diabetics. 25% of diabetics will acquire a non-healing ulcer in their lifetime; ~3 million diabetic ulcers annually. Diabetic foot ulcers lead to over 50,000 amputations annually at a cost that is estimated to exceed $5.1billion annually. Hospitalization costs of ~$20,000 for a patient with a DFU; ~$70,000 for an amputation. International Market Globally there are 382 million people living with diabetes and it is expected to reach 592 million by 2035, an increase of 55%. dermaPACE is CE Marked and currently marketed by independent distributors in Canada, Romania, Italy, S. Korea, Taiwan, Malaysia and Indonesia. dermaPACE can be licensed or joint ventured in these markets to speed market penetration while minimizing operating costs. Other Industries Could Unlock More Opportunities Including Licensing and Partnerships What makes the PACE technology even more valuable is that it isn’t limited to just health care. It has been patented for other uses as well, and can be used in energy, water, food, and industrial effluent markets. With so many different ways the technology can be utilized, it could open up a lot of different doors, and potentially attract the interest of big companies in other industries. Technical Analysis Based on our very own chart analysis we see very little downside risk, and an upside that almost looks too good to ignore. There is the potential for a move of over +50% in the near future. SNWV is currently trading at the lower end of its 52-week price channel. Less than a year ago, shares of SNWV were trading at over $0.60. A run back to those levels would show our members gains of over +200%! The float on SNWV is fairly thin at 40M, and we all know how fast these biotech stocks can move... We believe that SNWV could be our next trade alert to double in price! As such we are urging our members to start their research now, add it to the top of their watchlist, and consider grabbing a piece of SNWV this morning at 9:30AM EST. (*Remember to use a Stop-Loss Order or basic Limit Order to protect your gains, as well as limit possible losses.) Best Regards, The TopMarketGainer Team Don't Miss Our Next Huge Winner... Text 'GAINS' to '67076' to have our Trade Alerts Delivered Direct to your Cell Phone. (There is no charge. Msg&data rates may apply.) DISCLAIMER This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated and edited by both MJ Capital, LLC and PennyStockLocks, LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” refers to MJ Capital, LLC and PennyStockLocks, LLC. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature, and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions, and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website. We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. MJ Capital does NOT own any shares of the companies mentioned herewithin, nor intends to buy any in the future. MJ Capital’s business model is to receive financial compensation to promote public companies. We have been compensated ten thousand dollars by World Wide Holdings dba Invictus Resources to conduct investor relations advertising and marketing for SNWV. Any compensation is a major conflict of interest in our ability to be unbiased. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, MJ Capital often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.
SLong
by RedHotStocks
SNWV is on high alert. Trading at $0.20 w/ a $0.55 valuation + ===================== SNWV (SANUWAVE Health, Inc.) Float: 44.01M Alert Price: $0.205 Valuation: $0.55 (Zacks Small-Cap Research) Chart Analysis Investor Presentation Website | Recent News ======================== Members, Earlier today we promised to a bring you an up-and-coming biotech company that has the potential to double its share price in the immediate future. So without further ado, we ask that you turn your immediate attention to SNWV (SANUWAVE Health Inc.). Health care is big business, and researchers are always working on the next big treatment option that will revolutionize the industry. One area that doesn’t get much attention despite having a big need is the treatment of diabetic foot ulcers (DFUs), where SNWV has been focusing its efforts. Diabetes is a horrible disease, and especially as we continue to see the demographics of many countries get older, this is going to be a larger and growing market in the years to come. With a market cap of less than $30 million, SNWV is still relatively small and unknown, but we have a feeling that is going to change very soon… We see significant growth opportunities available for the SNWV thanks to the cutting edge technological advancements they have made thus far. Why their Technology is so Special SNWV has developed a technology that utilizes high-energy acoustic shock waves to help restore the natural healing process. Pulsed Acoustic Cellular Expression (PACE) is both proprietary and patented by Sanuwave, and is the prized technology that helps repair tissues and allows them to regenerate. Currently, patients with DFU simply have their wounds cleaned and are bandaged back up. With this technology, the wound can heal and improve both the quality of life for a patient and increase their lifespan. DFUs can end up leading to amputation and 65% of patients die within five years. SNWV currently has two products in their pipeline that could be lifesavers for patients in this multi-billion dollar market! dermaPACE, the company’s flagship device, is already FDA-approved in the US for treating DFUs, and has passed European standards for a CE marked device as well. The device has experienced growing demand into other parts of the world, and could see an even larger growth in demand as it becomes available to more patients. orthoPace, while not yet FDA-approved, is also a CE Marked device passing European standards. Both of these products utilize the PACE technology. SNWV has an All-Star CEO Kevin Richardson is the CEO of Sanuwave, and he’s got a good track record when it comes to health care. He previously developed “The Vac,” which is used for Negative Pressure Wound Therapy. The company that owned the product, Kinetic Concepts, went on to generate over $1 billion in revenue, and was ultimately taken private for around $11.5 billion. Sanuwave is nowhere near that value today, but with the guidance of its CEO, there’s a lot of hope that it could achieve similar success. Richardson has demonstrated an eye for value and opportunity, and his leadership ability will certainly help grow Sanuwave’s brand. SNWV Reports Record 2018 Financial Results SNWV witnessed revenue growth of +151% in 2018! The increase in revenue for 2018 was primarily due to initial sales of dermaPACE devices in the United States, an increase in sales of orthoPACE devices in Asia/Pacific and the European Community, as compared to the prior year, as well as higher sales of new applicators. 2018 was filled with achievements meant to prepare SANUWAVE for rapid revenue growth beginning in 2019 and beyond. The stage is set and it is now dependent on our ability to execute the well developed plan of placing 100 dermaPACE devices in the US in 2019. Our vision is to be viewed by the world as a diverse, compassionate global family that provides positive impact on life and environment, one shock at a time. The goal for SANUWAVE remains unchanged and that is to have a dermaPACE device anywhere and everywhere a DFU is treated. SNWV's Bullish Outlook for 2019 Sanuwave saw strong growth in 2018 and it expects 2019 to be even better, with device sales expected to reach 120 units. In five years, Sanuwave hopes to have as many as 2,000 placements and expects revenues to reach over $100 million. Additionally, the company is looking to continuing to build on its international presence this year as it hopes to expand into three to four more countries. There you have it, SNWV appears to be a clear cut winner from head to toe. The Company has: Strong Revenue Growth Innovative Products FDA Approval Seasoned Management Team A valuation that is +175% above its current share price Bullish Outlook for 2019 It's no surprise why we think SNWV's share price could double in the very near future. That being said, we suggest that you start your research now, and add SNWV to the top of your watchlist. About SANUWAVE Health, Inc. SANUWAVE Health, Inc. (www.sanuwave.com) is a shock wave technology company initially focused on the development and commercialization of patented noninvasive, biological response activating devices for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures. SANUWAVE’s portfolio of regenerative medicine products and product candidates activate biologic signaling and angiogenic responses, producing new vascularization and microcirculatory improvement, which helps restore the body’s normal healing processes and regeneration. SANUWAVE applies its patented PACE technology in wound healing, orthopedic/spine, plastic/cosmetic and cardiac conditions. Its lead product candidate for the global wound care market, dermaPACE®, is CE Marked throughout Europe and has device license approval for the treatment of the skin and subcutaneous soft tissue in Canada, Australia, and New Zealand. In the U.S., dermaPACE®, is currently under the FDA’s Premarket Approval (PMA) review process for the treatment of diabetic foot ulcers. SANUWAVE researches, designs, manufactures, markets and services its products worldwide, and believes it has demonstrated that its technology is safe and effective in stimulating healing in chronic conditions of the foot (plantar fasciitis) and the elbow (lateral epicondylitis) through its U.S. Class III PMA approved OssaTron® device, as well as stimulating bone and chronic tendonitis regeneration in the musculoskeletal environment through the utilization of its OssaTron®, Evotron® and orthoPACE® devices in Europe, Asia, and Asia/Pacific. In addition, there are license/partnership opportunities for SANUWAVE’s shock wave technology for non-medical uses, including energy, water, food, and industrial markets. Company Highlights & Recent Developments Accomplishments in 2018 Hired Shri Parikh, President Healthcare Received reimbursement tracking for DFU procedure Signed Premier Shockwave as the exclusive distributor for the VA and IHS Added Science Advisor, Dr. Perry Mayer JWC published a peer review article on SANUWAVE’s 336 double blind study Added 15 countries to international distribution Signed with NFS to help finance equipment growth Goals for 2019 100 US Placements ; 300 certified users Reimbursement; finish with at least 10 million covered lives Launch 2-3 domestic clinical studies Add 3-4 new countries Add Additional science advisors Add other key senior management hires To help facilitate its growth, Sanuwave partnered with Premier Shockwave, Inc., a leader for shockwave treatments used for podiatric and orthopedic applications. By working with Premier Shockwave, Inc., Sanuwave has been able to gain access into key markets in the United States, such as: Veteran’s Administration (VA) Indian Health Services (IHS) Tribally Operated Healthcare Services US Military Treatment Facilities (MTFs) Currently, Premier Shockwave serves and has access to more than 30 VA hospitals and MTFs. We expect another record breaking year for SNWV During the past year, the company hit record sales numbers and expanded into 15 new countries via partnerships, which could make this year even better. However, Sanuwave is not stopping there. It’s continuing on plans for international expansion, and it expects shipments to hit a new record in 2019. Find out which countries and regions are key to Sanuwave’s international growth by signing up for our exclusive report. Sanuwave is also continuing to conduct clinical studies, with between two and three planned for the U.S. to help with the rollout of its products. It’s also working with insurance providers to get reimbursement coverage, which would undoubtedly lead to more adoption of its products, and help grow sales even more. Sanuwave is an exciting young company that’s still in its early-growth stages. With great products that solve a big problem in a big market, it has all the ingredients for significant and rapid growth. Recent Developments SANUWAVE Receives U.S. and European Patents for Intracorporeal Shockwave Systems for Treating Blood Vessels in Cardiology and Endovascular Fields SUWANEE, GA, April 02, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- SANUWAVE Health, Inc. (SNWV), an emerging medical technology company focused on the development and commercialization of noninvasive, biological response activating devices in regenerative medicine, received United States Patent US 10,238,405 on March 26, 2019 entitled “Blood Vessel Treatment with Intracorporeal Pressure Shock Waves” which has a patent life up to January 2032 from the U.S. Patent and Trademark Office (USPTO). This U.S. patent includes eight (8) claims related to the special construction of the intracorporeal shockwave apparatuses/systems comprising of a catheter size fit within a blood vessel, with one or multiple shockwave applicators that include shockwave generation sources disposed within an ellipsoidal reflector oriented perpendicular to the catheter longitudinal central axis of symmetry, which can produce focused shockwaves oriented towards vessel’s wall where the plaques are forming. The shockwave generation sources can be electrohydraulic, laser-based, electromagnetic, or piezoelectric. Also, SANUWAVE received European Patent EP 3,117,784 on December 26, 2018 entitled “Usage of Intracorporeal Pressure Shock Waves in Medicine”, which has an expiration date in July 2030 from the European Patent Office (EPO). This patent is validated in designated countries including Denmark, Finland, France, Germany, Great Britain, Holland, Ireland, Italy, Norway, Spain, and Sweden. The European patent includes fifteen (15) claims related to the special construction of the intracorporeal shockwave devices/systems comprising of a catheter size fit within at least one of a blood vessel, graft, or artificial blood vessel, with at least one balloon, and at least one or multiple shockwave generation sources coupled to the catheter. The intracorporeal shockwave device/system can be used to treat plaques and obstructions together with distal protection devices, to protect the flowing of dislodged plaque particles to the heart or brain. The shockwave generation sources can be electrohydraulic, laser-based, electromagnetic, or piezoelectric. The use of intracorporeal shockwave systems can constitute a new therapy option in treating cardiovascular or endovascular arterial systems for partial obstructions due to atherosclerotic plaques or vulnerable plaques. The intracorporeal shockwave systems described in these patents can be used to treat blood vessels’ plaques and partial obstructions in conjunction with distal protection devices, to protect the flowing of dislodged plaque particles to the heart or brain, which can possess significant health hazard for the patient. Such intracorporeal shockwave systems can be also used to promote accelerated healing after angioplasty or stenting using metal bare stents or drug eluting stents; or to treat in-stent restenosis. “We have an extensive and growing Intellectual Property (IP) portfolio. It will make sense to maintain and grow some of the IP portfolio on our own as we develop our wound business. For other non-medical and various medical markets, we prefer to find good corporate partners, possibly in the atherosclerotic, cardiology, or endovascular space to bring the IP to a commercial stage. We plan to pursue monetization and partnering of our IP portfolio on a selective basis and will engage with vetted partners before the end of the year,” commented Kevin A. Richardson, II, CEO and Chairman of the Board at SANUWAVE. SANUWAVE Health Inc., and its wholly owned subsidiary SANUWAVE, Inc., now have 52 medical patents (issued or pending) and 22 non-medical patents (issued or pending) related to shockwave technology. Market Outlook The Market Could Potentially Hit Close to $50Billion by 2024 In the United States, as many as 1.9 million new cases of DFU are diagnosed every year. And in five years, it’s estimated that the market for DFU and pressure ulcers will potentially reach $4.9 billion. It’s a big industry that is in direct need of improved treatment options, and Sanuwave could help fill that void. Market Opportunity with The dermaPACE® System U.S Market Diabetic Foot Ulcers - $4B+ market size. 29 million people living with diabetes and 86 million pre-diabetics. 25% of diabetics will acquire a non-healing ulcer in their lifetime; ~3 million diabetic ulcers annually. Diabetic foot ulcers lead to over 50,000 amputations annually at a cost that is estimated to exceed $5.1billion annually. Hospitalization costs of ~$20,000 for a patient with a DFU; ~$70,000 for an amputation. International Market Globally there are 382 million people living with diabetes and it is expected to reach 592 million by 2035, an increase of 55%. dermaPACE is CE Marked and currently marketed by independent distributors in Canada, Romania, Italy, S. Korea, Taiwan, Malaysia and Indonesia. dermaPACE can be licensed or joint ventured in these markets to speed market penetration while minimizing operating costs. Other Industries Could Unlock More Opportunities Including Licensing and Partnerships What makes the PACE technology even more valuable is that it isn’t limited to just health care. It has been patented for other uses as well, and can be used in energy, water, food, and industrial effluent markets. With so many different ways the technology can be utilized, it could open up a lot of different doors, and potentially attract the interest of big companies in other industries. Technical Analysis Based on our very own chart analysis we see very little downside risk, and an upside that almost looks too good to ignore. There is the potential for a move of over +50% in the near future. SNWV is currently trading at the lower end of its 52-week price channel. Less than a year ago, shares of SNWV were trading at over $0.60. A run back to those levels would show our members gains of over +200%! The float on SNWV is fairly thin at 40M, and we all know how fast these biotech stocks can move... We believe that SNWV could be our next trade alert to double in price! As such we are urging our members to start their research now, add it to the top of their watchlist, and consider grabbing a piece of SNWV tomorrow morning at 9:30AM EST. (*Remember to use a Stop-Loss Order or basic Limit Order to protect your gains, as well as limit possible losses.) Best Regards, The PennyStock101 Team Don't Miss Our Next Huge Winner... Text 'PS101' to '67076' to have our Trade Alerts Delivered Direct to your Cell Phone. (There is no charge. Msg&data rates may apply.) DISCLAIMER This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated and edited by both MJ Capital, LLC and PennyStockLocks, LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” refers to MJ Capital, LLC and PennyStockLocks, LLC. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature, and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions, and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website. We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. MJ Capital does NOT own any shares of the companies mentioned herewithin, nor intends to buy any in the future. MJ Capital’s business model is to receive financial compensation to promote public companies. We have been compensated ten thousand dollars by World Wide Holdings dba Invictus Resources to conduct investor relations advertising and marketing for SNWV. Any compensation is a major conflict of interest in our ability to be unbiased. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, MJ Capital often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.
SLong
by DEXWireNews
1
Find out why $VICA could see Another +60pct Move... TOMORROW!===================== VICA (Rafina Innovations Inc.) Current Price: $0.3150 Float: 3.91M Chart Analysis Website | Recent News ======================== Members, A fresh trading week is upon us, and we have identified the perfect pick to kick it off with. Please turn your immediate attention to VICA (Rafina Innovations Inc.). Just like many of our recent winners, VICA trades on the OTC-QB, and has a tiny float of just 3.91M This is an exciting time for VICA, as the Company has gone through a rebranding period in order to better reflect their business objectives. Their revolutionary Flexisense™ technology has found demand for applications in many more industry sectors than was initially anticipated, and their portfolio of technologies have grown to include a much broader scope of innovations with application across numerous fields, including many outside the medical technology segment. In addition to healthcare technology, VICA is currently involved with projects related to Human Augmentation, Automotive safety and Smart Homes. One such project could be a game-changer in a multi-billion dollar market. VICA is currently developing cutting prototype for sleep apnoea through a biPAP machine that the Company's management believes can positively impact those with sleep apnoea, a respiratory failure which occurs during sleep. We see this as a major revenue generating opportunity for VICA. The sleep apnoea devices market is projected to reach USD 6.49 Billion by 2023 from an estimated USD 4.44 Billion in 2018, at a CAGR of 7.8%! VICA is another one of those tickers that could go viral in minutes, and has a history of tremendous single-day breakouts. In fact, just last week it ran up nearly +60% in just one session. We've done our own chart analysis, and see the potential for a move of up to +195%. This has the potential to be the next big winner for our members, and we want to see everyone on board. As such, we are urging all members to read our full profile on VICA, start their research now, and to add it to the top of their watchlist! About Rafina Innovations Inc. Rafina Innovations Inc. operates two fully owned subsidiaries: 1. HCi Viocare Technologies: developing hardware solutions aiming to empower the user by providing on demand information and enhancing living quality. The R&D center located in Glasgow, Scotland, is working on a large portfolio of cutting edge, revolutionary and disruptive technologies in the fields of Digital Health, Prosthetics, Orthotics, Diabetes, Assistive Devices, Sports & Wellbeing, and DVT. The Company has developed a unique sensing technology with the brand name Flexisense™, which uses a multitude of micro sensors to detect pressure as well as shear that is unique over other sensing technologies. The sensors are wirelessly connected to smart devices providing real time and on demand information. HCi Viocare Technologies works on a licensing business model. 2. HCi Viocare Clinics: creating the first cross-border independent chain of Prosthetics & Orthotics (P&O) and Diabetic Foot clinics in Europe. HCi Viocare’s Glasgow clinic is a subsidiary of HCi Viocare. Its founders Sotiris Leontaritis, a highly experienced entrepreneur and Dr Christos Kapatos, a Prosthetics and Orthotics expert and inventor, share a vision to improve people’s wellbeing in the face of a growing and correlated population of the obese, diabetic, amputated and/or movement impaired. To this end, HCi Viocare is establishing a chain of Prosthetic, Orthotic and diabetic foot rehabilitation centres in addition to implementing bioengineering innovations research and development in view of gaining licensing for health and wellness sectors. This Glasgow clinic, the only private P&O clinic in Scotland, is HCi Viocare’s first. It has evolved from the private practice of Bill Spence CPO, MBAPO, MISPO Certified Prosthetist Orthotist, founder and former chairman of the Association of Prosthetists and Orthotists (now BAPO) and former Chief of Research in Blatchford’s Clinical Services. Mr Spence played an integral role in the set-up of the rehabilitation suite and workshop, and hand-picked the P&O team responsible for client care. The clinic will serve as a key reference point and training centre for the HCi Viocare group of clinics, exporting British and International standards of care to under-served regions in the Mediterranean and Middle East. With a view to ensuring excellent practices and care, the company is supported by Professor Stephan Solomonidis, Bioengineer, F.I.MechE at the University of Strathclyde who, during his longstanding research and academic career has substantially contributed to the P&O International standards. Both Mr Spence and Prof Solomonidis supervised the company’s co-founder Dr Kapatos in obtaining his PhD at the University of Strathclyde, a globally renowned centre of excellence in bio-engineering. Please visit: www.rafinainnovations.com www.hci-viocare.co.uk Recent Developments for VICA Rafina Innovations Begins Development on a Prototype for Sleep Apnoea On February 14th, the Company announced that it recently commenced development on a prototype for sleep apnoea through a biPAP machine that management believes can positively impact those with sleep apnoea, a respiratory failure which occurs during sleep. Constantinos Zertalis, Rafina’s Chairman, President and CEO, commented: "Our research shows that 1 in 6 people suffer from respiratory failure that requires a biPAP machine. Further, solutions currently in the marketplace include equipment that tends to be large in size. Following investigation into the marketspace and needs of the consumer, our research and development team believe we can produce biPAP equipment that can be small in size, travel friendly and also energy efficient. Management expects the prototype to be ready between three to six months, and approximately the same size as a mobile phone. We believe our vision of this essential product will be attractive to the current market due to its small size, without sacrificing functionality, making it extremely convenient for users.” Market Outlook: The sleep apnoea devices market is projected to reach USD 6.49 Billion by 2023 from an estimated USD 4.44 Billion in 2018, at a CAGR of 7.8%. Growth in this market can primarily be attributed to factors such as the increasing prevalence of sleep apnoea globally owing to the increase of lifestyle diseases like obesity, initiatives by market players and the government to increase awareness regarding sleep apnoea, and the various technological advancements brought about by players to make the products comfortable for patients and thus increase patient compliance and adherence to the treatment. Technical Analysis: We love these low-float alerts, and their potential to breakout for monster single-day gains. Last week we watched VICA jump nearly +60% in just one session. Shares of VICA ran up from $0.24 to $0.38 last Thursday on light trade volume. With its low-float of just 3.91M, a nice boost in volume could send shares of VICA soaring ever higher than what we witnessed last Thursday. VICA was trading at over $1.00 less than 6-months ago. A run back to a dollar from today's alert price would show traders gains of over +212%! As we've mentioned above, we've done our own chart analysis, and see the potential for a move of up to +195%. We are anticipating another huge day for VICA tomorrow. This has the potential to be the next triple-digit gainer for our members. As such, we are urging all members to start their research on VICA, and to add it to the top of their watchlist! Best Regards, The TopMarketGainers Team Don't Miss Our Next Huge Winner... Text 'GAINS' to '67076' to have our Trade Alerts Delivered Direct to your Cell Phone. (There is no charge. Msg&data rates may apply.) Follow Us On Twitter: twitter.com DISCLAIMER This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated and edited by both MJ Capital, LLC and PennyStockLocks, LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” refers to MJ Capital, LLC and PennyStockLocks, LLC. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature, and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions, and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website. We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. MJ Capital does NOT own any shares of the companies mentioned herewithin, nor intends to buy any in the future. MJ Capital’s business model is to receive financial compensation to promote public companies. We have been compensated ten thousand dollars by s 3rd party to conduct investor relations advertising and marketing for VICA. Any compensation is a major conflict of interest in our ability to be unbiased. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, MJ Capital often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.
OTC:VICALong
by RedHotStocks
$PBIO has a Perfect Chart w/ Millions in Revenue, Low Float &...$PBIO has a Perfect Chart w/ Millions in Revenue, Low Float & Insider Buying: ===================== PBIO (Pressure BioSciences Inc.) Current Price: $2.19 Float: 1.65M Chart Analysis Investor Presentation ======================== Members, We hope you enjoyed the up to +56% in intraday gains that today's trade idea provided. If you liked today's trade action, you are going to love what we have in store for you next. Please turn your immediate attention to PBIO (Pressure BioSciences Inc.). Just like our most recent winner, this leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry, trades on the OTCQB, and has tight float of less than 2M. PBIO traded nicely today, closing the session up nearly three percent. We feel confident that this bullish momentum will continue onto tomorrow, as it appears that an uptrend is beginning to take shape. PBIO has also been getting plenty of positive press as of late. The Company’s President and CEO, Mr. Richard T. Schumacher, recently joined Stock Day’s Mr. Everett Jolly to discuss the Company's recent successes. During the interview Mr. Schumacher discussed PBIO's most recent achievements, all of which could be considered bullish catalysts in the immediate future: Their recent collaboration With NutraFuels, Inc., The Commercial Launch of Their BioPharmaceuticals Contract Services Business. The Publication of More Than Twenty Scientific Papers on the Company’s Unique Pressure-Based Products During 2018. On top of this, we also noticed some insider buying from PBIO's management in late December. This leads us to believe that PBIO's management considers the Company's stock price to be undervalued at the moment. PBIO also looks like a clear cut winner from a technical standpoint as well. We've done our own chart analysis, and we have to admit, we haven't seen a chart this pretty in quite some time. This appears to be a bottom-chart play, sitting on a golden pocket, with the potential to more than double in price. It looks like we have another big mover on our hands here with PBIO. That being said, we are urging all members to read our full profile, start their research now, and consider grabbing up a position in PBIO tomorrow morning at 9:30AM EST! About Pressure BioSciences, Inc. Pressure BioSciences, Inc. (PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry. Their products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or "PCT") hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). Their primary focus is in the development of high pressure-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, food science, soil & plant biology, forensics, and counter-bioterror applications. Additionally, PBIO is actively expanding the use of their pressure-based technologies in the following areas: (1) the use of their recently acquired technology from BaroFold, Inc. (the "Barofold" technology) to allow entry into the biologics manufacturing and contract research services sector, and (2) the use of their recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology ("UST") platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies. Investment Highlights Seasoned Management Team & Board of Directors Annual Revenue of $2.24M (FY2017) Three Novel, Enabling, Patent Protected, Proprietary Pressure-based Platforms Proven Core Technology (Over 300 PCT Systems Installed): Razor/Razorblade Business Model Sales into the Research Market (fast market penetration with minimal approvals required) Increasing Number of 3rd Party Publications from Marquee Laboratories PCT Breaks Through Bottlenecks and Barriers to Enable and Accelerate Scientific Discovery PreEMT Can Impact and Improve Protein Drug Therapeutics UST Offers the Potential to Produce Highly Stable Nanoemulsions, Including in the Food and CBD Markets Significant Multi-Billion Dollar Market Opportunity (~500K Scientists in 80K Labs Worldwide) Company Overview Three Business Segments - Three Unique Technology Platforms Research Products and Services (PCT Platform) PCT: Pressure Cycling Technology (alternating cycles of high/low pressure to control biomolecules) Focus: to improve the quality of biological sample preparation, one of the most crucial yet errorprone steps in all of scientific research, performed by tens of thousands of scientists worldwide in pharma, biotech, academia and government research laboratories. 15 Patents, 300 PCT Systems installed, 175+ customers, 120+ publications, 2017 revenue ($2.24M) Biological Contract Services (PreEMT Platform) PreEMT: Pressure Enabled Protein Manufacturing Technology Focus: to improve the quality of protein therapeutics, accelerate therapeutic protein development, and manufacture follow-on biologics by employing high pressure for disaggregation & controlled refolding of recombinant proteins into their native structures for desired drug activity. 8 Patents, Dec 2017 BaroFold Acquisition, Initial Contract Underway, Negotiating with Client #2 Nanoemulsion Manufacturing Services (UST Platform) UST: Ultra Shear Technology (combines high hydrostatic pressure & intense shear forces) Focus: to produce higher quality, more stable nanoemulsions with improved absorption, higher bioavailability, and lower surfactant levels: food, pharmaceuticals, nutraceuticals, cosmetics, lubricants, paint, and cannabis oil extracts (water soluble CBD) compared to standard emulsions Short-Term Growth Drivers Research Products & Services PCT Platform): New Next Generation Barocycler 2320EXTREME Additions to Sales & Marketing Team (one to four field sales managers in 2018) Novel Micro-Pestle Consumable…Potential Use in Pathology, etc. Four Additional PCT-based Instruments to be Released over Next 12 Months PBI Products Fill Existing Needs in $291B (2021 est.) Biopharmaceutical Market Biological Contract Services (PreEMT Platform): Consistent Revenue Stream fromServices to Protein Therapeutic Companies…plus the Potential for Millions of dollars from Royalties on Manufacturing Scale Licenses Nanoemulsion Manufacturing Services (UST Platform): Consistent Revenue Stream from Services to Food, Cosmetic, and Nutraceutical (CBD, CBG) Markets for Potential Development of Low Cost, Scalable Production of Nanoemulsions…plus the Potential for Millions of dollars from Royalties on Manufacturing Scale Licenses Recent Developments In late January PBIO announced news of a collaboration with NutraFuels Inc., to advance the development of a new generation of health and wellness nutraceutical products based on processing by PBI's proprietary Ultra Shear Technology (UST™) platform. The Companies believe that nanoemulsions prepared by the UST Platform will have improved quality and effectiveness compared to current emulsions, which will help to facilitate the development of a new generation of improved nutraceutical and other emulsion-based products, such as cosmetics. Edgar J. Ward, President and CEO of NTFU, said: "We pride ourselves in ensuring that we incorporate the highest level of quality possible in our manufactured products. When we heard that PBI was developing their new, proprietary UST processing platform, and learned of its potential to significantly increase the quality and effectiveness of nutraceutical products, we spoke with PBI and offered to help accelerate its commercial introduction. We are thrilled to be working with such experienced scientific leaders and innovators, in a program that we believe can change lives worldwide for the better." Mr. Ward continued: "We believe PBI's UST platform has the potential to create long-term room temperature stable, water-soluble nanoemulsions of oil-based solutions. Nanoemulsions are known to offer greater stability and bioavailability than the standard macroemulsions used today in nutraceuticals, cosmetics, and other industries. We are excited to have the opportunity to work with a life science industry leader in the optimization of a process that has the potential to bring higher quality not just to our products, but to nutraceutical products worldwide." Dr. Bradford A. Young, Chief Commercial Officer of PBI, commented: "We are pleased to have the opportunity to work with NTFU's scientists and manufacturing personnel in the development of new and improved nutraceutical products utilizing our UST platform. This proprietary technology employs ultra-high pressure and extreme shearing forces to create nano-scale emulsions of oil and water with long-term stability. For many oil-based products, the ability to create very small, nanometer-sized oil droplets that can effectively dissolve in water (nanoemulsions) can improve a product's appearance, sensory and medicinal benefits. There is a large and growing market opportunity for nutraceutical products with proven health and wellness benefits. We believe PBI's UST platform can help manufacturers accelerate growth and success in this market with higher quality, water-soluble, oil-based products with superior dietary absorption and shelf-life." Mr. Richard T. Schumacher, President and CEO of PBI, added: "We are excited to work with Edgar and his NTFU team in the optimization of our UST platform, which we believe will result in the development of new and beneficial health and wellness products. The staff at NTFU has years of experience in manufacturing nutraceutical products in a quality environment. They also have access to both raw materials and finished goods, both of which are needed for optimization. Finally, they have an existing analytical laboratory with state-of-the-art equipment and well-trained chemists who can perform testing on both pre and post-processed materials, which will be invaluable to the optimization process. This collaboration clearly supports both company's strategic objectives: we look forward to an exciting and mutually beneficial relationship with our colleagues at NutraFuels." Last month, PBIO announced the commercial launch of its Biopharmaceuticals Contract Services Business. The launch of this new business has been eagerly anticipated following the Company's acquisition of the assets of BaroFold, Inc. in December 2017, including patents, equipment, and other intellectual property relating to Barofold's unique, high pressure-based protein disaggregation and refolding platform. PBI expects that the unique Barofold technology platform will substantially improve the quality and costs of manufacturing protein therapeutics, by helping to resolve protein aggregation, improving solubility, and refolding complex misfolded protein therapeutic molecules into their desired, therapeutically-optimized conformations for improved drug efficacy and lower immunogenicity. Protein-based therapeutic drugs are a large and rapidly growing part of the global healthcare industry. There are over 200 therapeutic proteins and peptides approved for clinical use in the U.S. (THPdb database: crdd.osdd.net). Protein therapeutics are valued for their more potent and specific therapeutic effectiveness for many diseases, such as cancer and auto-immune disorders. They are also the preferred treatment choices for hormone and growth factor deficiencies. Research and Markets (May 2016) forecasted that the global protein drug market will grow to $248 billion by 2020. Market Outlook Proprietary Technology Platform Offers Improved Manufacturing for Protein Therapeutic Candidates and Positions PBIO to Service the $250 Billion Global Biopharmaceuticals Market The United States remains the largest medical device market in the world, with a market size of around $156 billion, and it represented about 40 percent of the global medical device market in 2017. U.S. exports of medical devices in key product categories identified by the Department of Commerce (DOC) exceeded $41 billion in that year. The medical technology industry (commonly referred to as medical devices) consists of articles, instruments, apparatuses, or machines that are used in the prevention, diagnosis or treatment of illness or disease, or for detecting, measuring, restoring, correcting, or modifying the structure or function of the body for some health purpose. Typically, the purpose of a medical device is not achieved by pharmacological, immunological, or metabolic means. The industry is responsible for almost 2 million jobs in the United States, including both direct and indirect employment. Medical technology directly accounts for well over 500,000 of these jobs. More than 80 percent of medical device companies in the United States consist of fewer than 50 employees, and many (notably start-up companies) have little or no sales revenue. The medical technology industry employs people in all 50 states. U.S. medical device companies are highly regarded globally for their innovative and high technology products. R&D spending continues to represent a high percentage of medical device industry expenditures, averaging 7 percent of revenue. Compared to several other industries including automotive, defense, and telecommunications, the medical device industry invests a higher percentage of yearly revenues into product innovation, reflecting the competitive nature of the industry and constant innovation and improvement of existing technologies. The medical device industry relies on several industries where the United States holds a competitive advantage, including microelectronics, telecommunications, instrumentation, biotechnology, and software development. Collaborations have led to recent advances including neuro-stimulators, stent technologies, biomarkers, robotic assistance, and implantable electronic devices. Since innovation fuels the medical device sector’s ongoing quest for better ways to treat and diagnose medical conditions, when coupled with patient life expectancy increasing and aging populations globally, the medical device sector should continue growing at a positive rate in the future. Technical Analysis AS we stated above, PBIO appears to be a clear cut winner from a technical standpoint as well. We've done our own chart analysis, and we have to admit, we haven't seen a chart this pretty in quite some time. This appears to be a bottom-chart play, sitting on a golden pocket, with the potential to more than double in price. PBIO has plenty of room to run from here. The Company is currently down fifty-six percent from its 52-week high of $5.00. A run back to that high would show traders over +128% in pure profit from today's alert price. Let's also not forget that the float for PBIO is ridiculously thin at just 1.65M. With a float that tight, PBIO has the potential to break out for significant gains should it see a sudden burst in trade volume. If any market friendly news were to be released, we could see shares of PBIO sky-rocket! We are urging all members to start their research now, and consider grabbing up a position in PBIO tomorrow morning at 9:30AM EST! (*Remember to use a Stop-Loss Order or basic Limit Order to protect your gains, as well as limit possible losses.) Best Regards, The TopMarketGainers Team Don't Miss Our Next Huge Winner... Text 'GAINS' to '67076' to have our Trade Alerts Delivered Direct to your Cell Phone. (There is no charge. Msg&data rates may apply.) DISCLAIMER This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated and edited by both MJ Capital, LLC and PennyStockLocks, LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” refers to MJ Capital, LLC and PennyStockLocks, LLC. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature, and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions, and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website. We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. MJ Capital does NOT own any shares of the companies mentioned herewithin, nor intends to buy any in the future. MJ Capital’s business model is to receive financial compensation to promote public companies. We have been compensated ten thousand dollars by the Financial Marketing Group to conduct investor relations advertising and marketing for PBIO. Any compensation is a major conflict of interest in our ability to be unbiased. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, MJ Capital often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.
OTC:PBIOLong
by RedHotStocks